Clinical Trial Registries and Result Disclosure

WHO Position on Clinical Trial Disclosure

Posted on digi By digi

The World Health Organization (WHO) plays a pivotal role in setting global expectations for transparency in clinical research. In 2017, the WHO issued a Joint Statement on public disclosure of clinical trial results, underscoring the ethical and scientific necessity of registering trials and reporting results within defined timelines. This initiative forms the backbone of global transparency norms and applies to all interventional clinical trials, regardless of sponsor type or geographic location.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

The AllTrials Campaign: Progress and Challenges

Posted on digi By digi

The AllTrials Campaign was launched in 2013 as a global movement to demand that all clinical trials—past and present—be registered and have their results reported. Initiated by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, the campaign quickly gained international traction and has since reshaped conversations around clinical transparency, ethics, and accountability in medical research.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

The AllTrials Campaign: Progress and Challenges

Posted on digi By digi

Launched in 2013, the AllTrials campaign became a defining movement in the fight for full transparency in clinical research. Led by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, AllTrials raised global awareness of the problem of hidden and unreported clinical trial results—particularly those with negative or inconclusive outcomes.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

The AllTrials Campaign: Progress and Challenges

Posted on digi By digi

The AllTrials campaign was launched in January 2013 by a coalition of advocacy groups and scientific leaders including Sense About Science, the BMJ, the Cochrane Collaboration, and Ben Goldacre. Its core message was simple yet bold: “All trials registered. All results reported.” This call to action was directed toward pharmaceutical companies, regulatory authorities, universities, and journals that were collectively responsible for a long-standing issue in biomedical research—non-disclosure of trial results.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

Voluntary Transparency Programs by Clinical Trial Sponsors

Posted on digi By digi

While regulatory frameworks mandate a baseline for clinical trial result disclosure, an increasing number of pharmaceutical companies are going beyond what is legally required. These voluntary transparency programs are initiatives led by trial sponsors to proactively register studies, publish summary results, and share datasets. The motivation is multifaceted: ethical responsibility, public trust, regulatory goodwill, and competitive positioning.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

Data Sharing Agreements and Ethics in Clinical Trials

Posted on digi By digi

As global healthcare moves toward transparency and evidence-based decision-making, the sharing of clinical trial data has become an ethical and scientific expectation. Sponsors, CROs, regulators, and academic institutions increasingly engage in controlled data sharing to validate findings, generate real-world evidence, and reduce research duplication.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

Cross-Jurisdictional Transparency Regulations in Clinical Trials

Posted on digi By digi

In the pharmaceutical world, transparency in clinical trial conduct and result disclosure is no longer optional—it’s a regulatory mandate. However, what constitutes transparency can vary drastically across jurisdictions. A clinical trial conducted across the US, EU, Canada, and Asia must adhere to a complex mesh of local, regional, and global rules for trial registration, summary result disclosure, and participant data handling.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

Patient Advocacy and Trial Transparency

Posted on digi By digi

In recent years, patient advocacy has transformed from a passive presence to an active force shaping the direction of clinical research. No longer confined to the sidelines, patients and advocacy groups now demand access to information, influence on trial design, and accountability in how results are disclosed. This movement, rooted in the principle of patient centricity, has significant implications for clinical trial transparency.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives

Trends in Open Access Clinical Trial Data

Posted on digi By digi

Open access clinical trial data refers to the publicly available datasets generated during the conduct of interventional or observational trials. These datasets can range from summary-level outcomes to anonymized participant-level data (PLD). The core objective is to promote transparency, enable independent analysis, and accelerate innovation in drug development and public health research.
Click to read the full article.

Clinical Trial Registries and Result Disclosure, Transparency Initiatives